Comment on "Evaluation of anticancer therapy-related dermatologic adverse events: Insights from Food and Drug Administration's adverse event reporting system dataset"

J Am Acad Dermatol. 2024 Dec 9:S0190-9622(24)03331-0. doi: 10.1016/j.jaad.2024.10.117. Online ahead of print.
No abstract available

Keywords: cutaneous adverse drug reactions; disproportionality analysis; pharmacovigilance.

Publication types

  • Letter